Charles Schwab
RPRX icon

Charles Schwab’s Royalty Pharma RPRX Stock Holding History

Charles Schwab’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173M Buy
3,083,528
+55,629
+2% +$2.9M 0.02% 517
2026
Q1 		$145M Buy
3,027,899
+114,501
+4% +$5.01M 0.02% 549
2025
Q4 		$113M Sell
2,913,398
-112,314
-4% -$4.28M 0.02% 672
2025
Q3 		$107M Buy
3,025,712
+16,875
+0.6% +$611K 0.02% 676
2025
Q2 		$108M Sell
3,008,837
-113,694
-4% -$3.77M 0.02% 644
2025
Q1 		$97.2M Sell
3,122,531
-9,097
-0.3% -$288K 0.02% 667
2024
Q4 		$79.9M Buy
3,131,628
+130,025
+4% +$3.45M 0.01% 796
2024
Q3 		$84.9M Buy
3,001,603
+1,103,341
+58% +$30.6M 0.02% 765
2024
Q2 		$50.1M Buy
1,898,262
+65,257
+4% +$1.81M 0.01% 1076
2024
Q1 		$55.7M Buy
1,833,005
+62,017
+4% +$1.83M 0.01% 964
2023
Q4 		$49.7M Buy
1,770,988
+122,084
+7% +$3.35M 0.01% 978
2023
Q3 		$44.8M Buy
1,648,904
+173,315
+12% +$5.15M 0.01% 953
2023
Q2 		$45.4M Buy
1,475,589
+68,052
+5% +$2.3M 0.01% 913
2023
Q1 		$50.7M Buy
1,407,537
+46,358
+3% +$1.72M 0.02% 819
2022
Q4 		$53.8M Buy
1,361,179
+83,896
+7% +$3.5M 0.02% 759
2022
Q3 		$51.3M Buy
1,277,283
+109,998
+9% +$4.7M 0.02% 741
2022
Q2 		$49.1M Buy
1,167,285
+92,864
+9% +$3.81M 0.02% 763
2022
Q1 		$41.9M Buy
1,074,421
+86,335
+9% +$3.39M 0.01% 993
2021
Q4 		$39.4M Buy
988,086
+41,987
+4% +$1.63M 0.01% 1076
2021
Q3 		$34.2M Buy
946,099
+680,274
+256% +$26.4M 0.01% 1124
2021
Q2 		$10.9M Buy
265,825
+20,688
+8% +$880K ﹤0.01% 1952
2021
Q1 		$10.7M Buy
245,137
+64,636
+36% +$3.06M ﹤0.01% 1924
2020
Q4 		$9.04M Sell
180,501
-34,354
-16% -$1.46M ﹤0.01% 1923
2020
Q3 		$9.04M Buy
214,855
+53,188
+33% +$2.28M ﹤0.01% 1762
2020
Q2 		$7.85M Buy
+161,667
New +$8M ﹤0.01% 1787

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab's RPRX Position: Q2 2026 in Review

Charles Schwab increased its Royalty Pharma (RPRX) stake by 1.8% in Q2 2026, buying an estimated $2.9M and bringing the position to 3,083,528 shares worth $173M. The position accounts for 0.02% of the portfolio, ranked #517.

Charles Schwab first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Charles Schwab held 3,083,528 shares of Royalty Pharma worth $173M as of Q2 2026.
  • Charles Schwab bought 55,629 Royalty Pharma shares in Q2 2026, an estimated $2.9M.
  • Royalty Pharma made up 0.02% of Charles Schwab's portfolio in Q2 2026, its #517 holding.
  • Charles Schwab first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.